These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 14520369)

  • 1. Has gene therapy for ALS arrived?
    Miller TM; Cleveland DW
    Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyotrophic lateral sclerosis and gene therapy.
    Miller TM; Smith RA; Cleveland DW
    Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
    [No Abstract]   [Full Text] [Related]  

  • 3. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
    Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
    Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
    Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
    Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of mice, men and motor neurons.
    Newbery HJ; Abbott CM
    Trends Mol Med; 2002 Feb; 8(2):88-92. PubMed ID: 11815275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Edaravone in ALS.
    Takahashi R
    Exp Neurol; 2009 Jun; 217(2):235-6. PubMed ID: 19285071
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy.
    Acsadi G; Anguelov RA; Yang H; Toth G; Thomas R; Jani A; Wang Y; Ianakova E; Mohammad S; Lewis RA; Shy ME
    Hum Gene Ther; 2002 Jun; 13(9):1047-59. PubMed ID: 12067438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy for ALS: progress and prospects.
    Azzouz M
    Biochim Biophys Acta; 2006; 1762(11-12):1122-7. PubMed ID: 16806843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
    Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
    Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
    Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 12. RNA interference protects against ALS in mouse model.
    Burton A
    Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
    [No Abstract]   [Full Text] [Related]  

  • 13. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment.
    Goodall EF; Morrison KE
    Expert Rev Mol Med; 2006 May; 8(11):1-22. PubMed ID: 16723044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis.
    Chang-Hong R; Wada M; Koyama S; Kimura H; Arawaka S; Kawanami T; Kurita K; Kadoya T; Aoki M; Itoyama Y; Kato T
    Exp Neurol; 2005 Jul; 194(1):203-11. PubMed ID: 15899257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental therapies hold promise for treating amyotrophic lateral sclerosis.
    Friedrich MJ
    JAMA; 2005 Mar; 293(9):1048-9. PubMed ID: 15741517
    [No Abstract]   [Full Text] [Related]  

  • 16. Are all new data referring to amyotrophic lateral sclerosis certain? Some doubts.
    Rafałowska J
    Folia Neuropathol; 2001; 39(4):261-4. PubMed ID: 11928897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA.
    Wang J; Xu G; Slunt HH; Gonzales V; Coonfield M; Fromholt D; Copeland NG; Jenkins NA; Borchelt DR
    Neurobiol Dis; 2005 Dec; 20(3):943-52. PubMed ID: 16046140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life.
    Brooks BR
    Ann Neurol; 2009 Jan; 65 Suppl 1():S17-23. PubMed ID: 19191306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS.
    Cleveland DW; Rothstein JD
    Nat Rev Neurosci; 2001 Nov; 2(11):806-19. PubMed ID: 11715057
    [No Abstract]   [Full Text] [Related]  

  • 20. Determinants of rapid disease progression in ALS.
    Yamanaka K; Cleveland DW
    Neurology; 2005 Dec; 65(12):1859-60. PubMed ID: 16380607
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.